Track the Quince Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €29.5m. The latest transaction was disclosed on 29 December 2025 (J). Among the most active insiders: Thye Dirk. All data is free.
24
Insider Decl.
n/a
Thresholds
€568,671
12 ops.
Buy Volume
€148,942
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Quince Therapeutics, Inc. Buy (bullish), based on 4 analysts. Average price target: US$82.75.
50Σ signal
Buys €568,671€148,942 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
1,520 shares@ US$1.6447.0% of flowCommon StockSEC:0001209191-22-049221:0
24 of 24 declarations
Acerca de Quince Therapeutics, Inc.
Quince Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para enfermedades neurodegenerativas. Emplea enfoques innovadores para mejorar la calidad de vida de los pacientes.